dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse


Our Discord Notification Server invitation link is https://discord.gg/jB2qmRrxyD

Author Topic: How I Recommend We Treat Methamphetamine Use Disorder  (Read 18 times)

Offline smfadmin (OP)

  • SMF (internal) Site
  • Administrator
  • Sr. Member
  • *****
  • Join Date: Dec 2014
  • Location: Management
  • Posts: 551
  • Reputation Power: 0
  • smfadmin has hidden their reputation power
  • Last Login:Today at 05:20:17 AM
  • Supplied Install Member
**Same Class Substitution for Meth Dependence:

No "official" approved pharmacotherapy exists for methamphetamine dependence anywhere in the world and that's because there isn't a "Methadone" or "Suboxone" for Meth Use Disorder, so options like mine are never made available to those that want to get off the "train", and that is just plain wrong - it's better to go with something like this than with nothing at all !

So after decades of thought, this is what I consider to be the "next best thing" and I reckon that it is worth a shot.

Unlike opioids, stimulant dependence has no adopted maintenance model but a growing evidence base points toward one: same-class substitution, replacing the illicit drug with a regulated, oral, stimulant ... It's the Methadone or Suboxone concept except for the the "long lasting" bit, which is actually a good thing, as it's more controllable this way.

**The trials and dosages (this data is in the public domain and was taken from in internet):

Wodak's 2001 NDARC pilot (n=41, dexamphetamine 21–60mg/day) tested feasibility at modest doses — improved counselling attendance, no clear drop in use.

Longo et al. (2010, n=49, Adelaide) pushed dosing to a 110mg ceiling (~80mg average), supervised daily: retention roughly doubled, dependence severity significantly lower at follow-up, no serious adverse events but still no significant reduction in use on objective measures.

Galloway (2011) echoed that pattern with sustained-release dextroamphetamine.

Ezard's LiMA trial (2024–25, n=164, lisdexamfetamine 250mg) found a real reduction in use-days across the treatment window and much higher satisfaction, though the effect faded and missed significance at the primary endpoint.

Trial conclusion:

Twenty years, three drugs, same message: substitution reliably improves retention and stability, and reliably struggles a bit, I admit, but does actually reduce harm.

**Why higher doses are better:

Long-term meth use down-regulates dopaminergic receptors substantially. Underdosing a high-tolerance user isn't the cautious option, it's a predictable way to get nothing. That's the vodka-to-beer problem: the alcohol's still there, the effect's still real, but nowhere near what the system has adapted to. Longo and LiMA both moved dosing up from Wodak's original pilot range, and both outperformed it on retention and severity, consistent with that idea, although I must admit it's not prefect.

**Why it works when it works:

It's not really about recreating the meth trip; oral dosing is slow-onset by design, which trashes the instant-reinforcement loop that IV or smoking ice creates so you get back to the normal rhythm.

Shorter-acting stimulants also "burn off" over hours rather than the ~12-hour meth run, which is a big part of why sleep normalises actual sleep architecture, not just feeling less wired ... the user is active enough to wanna crash around bedtime.

Euphoria and reinforcement aren't the same thing either: meth's extra methyl group makes it far more lipid-soluble, crossing the blood-brain barrier passively rather than through transporters, which is part of why it's both more reinforcing and more neurotoxic than its pharmaceutical cousins at escalating exposure (pinched from Google).

The goal isn't to copy the high — it's stabilisation: broken binge-crash cycles, restored sleep, contaminated supply removed, a platform stable enough to see the psychosocial benefits.

**Why cross-class substitution fails:

Using opioids to blunt stimulant cravings just stacks a second, harder-to-treat dependence on top of cravings that never left. Stimulant dependence gets stabilised with stimulants, that's the whole point, not a side note.

The poor user is not chained to another rigid treatment program designed for Heroin addicts - the last thing they need !

None of this is consensus. LiMA missed its own primary endpoint. It's real, cautious signal, not a solved problem — and I'd still say it's not the right call for all people, just possibly useful for those who are sincerely committed to stay engaged long enough for everything to work.
friendly
0
funny
0
informative
0
agree
0
disagree
0
like
0
dislike
0
No reactions
No reactions
No reactions
No reactions
No reactions
No reactions
No reactions
measure twice, cut once

Tags:
 

Related Topics

  Subject / Started by Replies Last post
5 Replies
1252 Views
Last post January 23, 2016, 03:11:46 AM
by Snout
0 Replies
23949 Views
Last post June 24, 2018, 03:35:07 AM
by Chip
0 Replies
22813 Views
Last post June 17, 2019, 07:27:56 PM
by Chip
0 Replies
59 Views
Last post September 29, 2019, 12:15:14 PM
by Chip
0 Replies
22571 Views
Last post December 31, 2023, 02:40:52 AM
by Chip
0 Replies
15514 Views
Last post November 16, 2024, 05:09:18 AM
by Chip
0 Replies
13504 Views
Last post January 17, 2025, 03:19:52 PM
by smfadmin
0 Replies
253 Views
Last post June 19, 2026, 06:42:36 PM
by Chip
0 Replies
86 Views
Last post July 08, 2026, 09:59:14 AM
by smfadmin
1 Replies
146 Views
Last post July 08, 2026, 11:17:01 AM
by smfadmin


dopetalk does not endorse any advertised product nor does it accept any liability for it's use or misuse





TERMS AND CONDITIONS

In no event will d&u or any person involved in creating, producing, or distributing site information be liable for any direct, indirect, incidental, punitive, special or consequential damages arising out of the use of or inability to use d&u. You agree to indemnify and hold harmless d&u, its domain founders, sponsors, maintainers, server administrators, volunteers and contributors from and against all liability, claims, damages, costs and expenses, including legal fees, that arise directly or indirectly from the use of any part of the d&u site.


TO USE THIS WEBSITE YOU MUST AGREE TO THE TERMS AND CONDITIONS ABOVE


Founded December 2014
SimplePortal 2.3.6 © 2008-2014, SimplePortal